PUBLISHER: KBV Research | PRODUCT CODE: 1093394
PUBLISHER: KBV Research | PRODUCT CODE: 1093394
LAMEA Human Microbiome Market Size, Share & Industry Trends Analysis Report By Product, By Disease Type, By Technology, By Application, By Type, By Country and Growth Forecast, 2022 - 2028
The Latin America, Middle East and Africa Human Microbiome Market would witness market growth of 35.8% CAGR during the forecast period (2022-2028).
The gut microbiota has a considerable impact on the health of its host. These organisms carry out biochemical processes that impact carcinogenesis, tumor formation, and immune treatment response. Continuous intra-abdominal infections, antimicrobial medicines, or both may raise the risk of colorectal cancer. End products generated by the gut microbiota also have an impact on intestinal cell coverage, either stimulating or inhibiting tumorigenesis. Aside from colorectal cancer, the intestinal microbiota has been demonstrated to play a role in extra-intestinal cancers such as hepatocellular carcinoma by allowing organisms to spread to other areas of the body. Additionally, H. pylori is linked to an increased risk of stomach cancer in humans. Fusobacterium and Clostridium are heavily represented in people with stomach cancer. In the case of breast cancer, environmental and host variables have a direct impact on the disease's progression. Bacterial populations, on the other hand, may cause breast cancer. When compared to healthy people, those with breast cancer have higher Bacillus, Staphylococcus, and Enterobacteriaceae in their breast tissue.
In this region, Cardiovascular diseases have a major foothold. According to the National Library of Medicine, cardiovascular disease is the main cause of mortality among Abu Dhabi residents. Despite the tremendous effort and resource investment, this has not improved over time. Over 39% of deaths in people over 45 years old were due to cardiovascular disease. CVD kills more people over the age of 60 than cancer, respiratory disorders, and infectious diseases combined. A bad diet is the major cause of CVD mortality, with one study estimating that the existing diet was responsible for 72% of CVD deaths in the United Arab Emirates (UAE). In the United Arab Emirates, low consumption of whole grains was linked to 22% of CVD-related deaths. Consumption of processed meat, red meat, and sugar-sweetened beverages are further risk factors.
Despite survey participants' understanding of what comprises healthy eating and exercise habits, impediments to lifestyle change abound. Only 3% of the 390 people surveyed in a UAE study with type 2 diabetes fulfilled the standards' weekly requirements for 150 minutes of moderate-intensity aerobic activity or 90 minutes of vigorous aerobic activity. Cultural reasons (29.2%) and a lack of family support (4.1) were the most common reasons reported in that study for not exercising. With the increasing cases of cardiovascular diseases, the requirement for an effective treatment method is increasing. Therefore, the growth of the regional human microbiomes market is increasing due to the fact that they are effective in boosting the effectiveness of prevention and treatment drugs for CVDs.
The Brazil market dominated the LAMEA Human Microbiome Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $19.8 million by 2028. The Argentina market is anticipated to grow at a CAGR of 36.6% during (2022 - 2028). Additionally, The UAE market would showcase a CAGR of 35.5% during (2022 - 2028).
Based on Product, the market is segmented into Drugs, Diagnostic Tests, Probiotics, Prebiotics, and Others. Based on Disease Type, the market is segmented into Infectious Diseases, Endocrine & Metabolic Disorders, Gastrointestinal Diseases, Cancer, and Others. Based on Technology, the market is segmented into Genomics, Proteomics and Metabolomics. Based on Application, the market is segmented into Therapeutics and Diagnostics. Based on Type, the market is segmented into Microbiome Consortia Transplantation (FMT), Peptide, Live Biotherapeutic Product and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Seres Therapeutics, Inc., 4D pharma plc, OptiBiotix Health Plc, Synlogic, Inc., Second Genome, Inc., Vedanta Biosciences, Inc., Finch Therapeutics Group, Inc., Ferring Holdings SA, and Enterome.
Scope of the Study
Market Segments covered in the Report:
By Product
- Drugs
- Diagnostic Tests
- Probiotics
- Prebiotics, and
- Others
By Disease Type
- Infectious Diseases
- Endocrine & Metabolic Disorders
- Gastrointestinal Diseases
- Cancer, and
- Others
By Technology
- Genomics
- Proteomics
- Metabolomics
By Application
- Therapeutics
- Diagnostics
By Type
- Microbiome Consortia Transplantation (FMT)
- Peptide
- Live Biotherapeutic Product
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Seres Therapeutics, Inc.
- 4D pharma plc
- OptiBiotix Health Plc
- Synlogic, Inc.
- Second Genome, Inc.
- Vedanta Biosciences, Inc.
- Finch Therapeutics Group, Inc.
- Ferring Holdings SA
- Enterome
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 LAMEA Human Microbiome Market, by Product
- 1.4.2 LAMEA Human Microbiome Market, by Disease Type
- 1.4.3 LAMEA Human Microbiome Market, by Technology
- 1.4.4 LAMEA Human Microbiome Market, by Application
- 1.4.5 LAMEA Human Microbiome Market, by Type
- 1.4.6 LAMEA Human Microbiome Market, by Country
- 1.5 Methodology for the research
Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market composition and scenario
- 2.1.1 Overview
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
Chapter 3. LAMEA Human Microbiome Market by Product
- 3.1 LAMEA Drugs Market by Country
- 3.2 LAMEA Diagnostic Tests Market by Country
- 3.3 LAMEA Probiotics Market by Country
- 3.4 LAMEA Prebiotics Market by Country
- 3.5 LAMEA Others Market by Country
Chapter 4. LAMEA Human Microbiome Market by Disease Type
- 4.1 LAMEA Infectious Diseases Market by Country
- 4.2 LAMEA Endocrine & Metabolic Disorders Market by Country
- 4.3 LAMEA Gastrointestinal Diseases Market by Country
- 4.4 LAMEA Cancer Market by Country
- 4.5 LAMEA Others Market by Country
Chapter 5. LAMEA Human Microbiome Market by Technology
- 5.1 LAMEA Genomics Market by Country
- 5.2 LAMEA Proteomics Market by Country
- 5.3 LAMEA Metabolomics Market by Country
Chapter 6. LAMEA Human Microbiome Market by Application
- 6.1 LAMEA Therapeutics Market by Country
- 6.2 LAMEA Diagnostics Market by Country
Chapter 7. LAMEA Human Microbiome Market by Type
- 7.1 LAMEA Microbiome Consortia Transplantation (FMT) Market by Country
- 7.2 LAMEA Peptide Market by Country
- 7.3 LAMEA Live Biotherapeutic Product Market by Country
- 7.4 LAMEA Others Market by Country
Chapter 8. LAMEA Human Microbiome Market by Country
- 8.1 Brazil Human Microbiome Market
- 8.1.1 Brazil Human Microbiome Market by Product
- 8.1.2 Brazil Human Microbiome Market by Disease Type
- 8.1.3 Brazil Human Microbiome Market by Technology
- 8.1.4 Brazil Human Microbiome Market by Application
- 8.1.5 Brazil Human Microbiome Market by Type
- 8.2 Argentina Human Microbiome Market
- 8.2.1 Argentina Human Microbiome Market by Product
- 8.2.2 Argentina Human Microbiome Market by Disease Type
- 8.2.3 Argentina Human Microbiome Market by Technology
- 8.2.4 Argentina Human Microbiome Market by Application
- 8.2.5 Argentina Human Microbiome Market by Type
- 8.3 UAE Human Microbiome Market
- 8.3.1 UAE Human Microbiome Market by Product
- 8.3.2 UAE Human Microbiome Market by Disease Type
- 8.3.3 UAE Human Microbiome Market by Technology
- 8.3.4 UAE Human Microbiome Market by Application
- 8.3.5 UAE Human Microbiome Market by Type
- 8.4 Saudi Arabia Human Microbiome Market
- 8.4.1 Saudi Arabia Human Microbiome Market by Product
- 8.4.2 Saudi Arabia Human Microbiome Market by Disease Type
- 8.4.3 Saudi Arabia Human Microbiome Market by Technology
- 8.4.4 Saudi Arabia Human Microbiome Market by Application
- 8.4.5 Saudi Arabia Human Microbiome Market by Type
- 8.5 South Africa Human Microbiome Market
- 8.5.1 South Africa Human Microbiome Market by Product
- 8.5.2 South Africa Human Microbiome Market by Disease Type
- 8.5.3 South Africa Human Microbiome Market by Technology
- 8.5.4 South Africa Human Microbiome Market by Application
- 8.5.5 South Africa Human Microbiome Market by Type
- 8.6 Nigeria Human Microbiome Market
- 8.6.1 Nigeria Human Microbiome Market by Product
- 8.6.2 Nigeria Human Microbiome Market by Disease Type
- 8.6.3 Nigeria Human Microbiome Market by Technology
- 8.6.4 Nigeria Human Microbiome Market by Application
- 8.6.5 Nigeria Human Microbiome Market by Type
- 8.7 Rest of LAMEA Human Microbiome Market
- 8.7.1 Rest of LAMEA Human Microbiome Market by Product
- 8.7.2 Rest of LAMEA Human Microbiome Market by Disease Type
- 8.7.3 Rest of LAMEA Human Microbiome Market by Technology
- 8.7.4 Rest of LAMEA Human Microbiome Market by Application
- 8.7.5 Rest of LAMEA Human Microbiome Market by Type
Chapter 9. Company Profiles
- 9.1 Ferring Holdings SA
- 9.1.1 Company Overview
- 9.1.2 Financial Analysis
- 9.1.3 Regional Analysis
- 9.1.4 Research and Development Expense
- 9.1.5 Recent Strategies and Developments:
- 9.1.5.1 Partnerships, Collaborations, and Agreements:
- 9.2 Enterome
- 9.2.1 Company Overview
- 9.2.2 Recent Strategies and Developments:
- 9.2.2.1 Partnerships, Collaborations, and Agreements:
- 9.3 Seres Therapeutics, Inc.
- 9.3.1 Company Overview
- 9.3.2 Financial Analysis
- 9.3.3 Research & Development Expense
- 9.3.4 Recent Strategies and Developments:
- 9.3.4.1 Partnerships, Collaborations, and Agreements:
- 9.4 4D Pharma Plc
- 9.4.1 Company Overview
- 9.4.2 Financial Analysis
- 9.4.3 Research & Development Expense
- 9.4.4 Recent Strategies and Developments:
- 9.4.4.1 Partnerships, Collaborations, and Agreements:
- 9.5 OptiBiotix Health Plc
- 9.5.1 Company Overview
- 9.6 Synlogic, Inc.
- 9.6.1 Company Overview
- 9.6.2 Financial Analysis
- 9.6.3 Research & Development Expense
- 9.7 Second Genome, Inc.
- 9.7.1 Company Overview
- 9.8 Vedanta Biosciences, Inc.
- 9.8.1 Company Overview
- 9.9 Finch Therapeutics Group, Inc.
- 9.9.1 Company Overview
- 9.9.2 Financial Analysis
- 9.9.3 Research & Development Expense
LIST OF TABLES
- TABLE 1 LAMEA Human Microbiome Market, 2018 - 2021, USD Thousands
- TABLE 2 LAMEA Human Microbiome Market, 2022 - 2028, USD Thousands
- TABLE 3 LAMEA Human Microbiome Market by Product, 2018 - 2021, USD Thousands
- TABLE 4 LAMEA Human Microbiome Market by Product, 2022 - 2028, USD Thousands
- TABLE 5 LAMEA Drugs Market by Country, 2018 - 2021, USD Thousands
- TABLE 6 LAMEA Drugs Market by Country, 2022 - 2028, USD Thousands
- TABLE 7 LAMEA Diagnostic Tests Market by Country, 2018 - 2021, USD Thousands
- TABLE 8 LAMEA Diagnostic Tests Market by Country, 2022 - 2028, USD Thousands
- TABLE 9 LAMEA Probiotics Market by Country, 2018 - 2021, USD Thousands
- TABLE 10 LAMEA Probiotics Market by Country, 2022 - 2028, USD Thousands
- TABLE 11 LAMEA Prebiotics Market by Country, 2018 - 2021, USD Thousands
- TABLE 12 LAMEA Prebiotics Market by Country, 2022 - 2028, USD Thousands
- TABLE 13 LAMEA Others Market by Country, 2018 - 2021, USD Thousands
- TABLE 14 LAMEA Others Market by Country, 2022 - 2028, USD Thousands
- TABLE 15 LAMEA Human Microbiome Market by Disease Type, 2018 - 2021, USD Thousands
- TABLE 16 LAMEA Human Microbiome Market by Disease Type, 2022 - 2028, USD Thousands
- TABLE 17 LAMEA Infectious Diseases Market by Country, 2018 - 2021, USD Thousands
- TABLE 18 LAMEA Infectious Diseases Market by Country, 2022 - 2028, USD Thousands
- TABLE 19 LAMEA Endocrine & Metabolic Disorders Market by Country, 2018 - 2021, USD Thousands
- TABLE 20 LAMEA Endocrine & Metabolic Disorders Market by Country, 2022 - 2028, USD Thousands
- TABLE 21 LAMEA Gastrointestinal Diseases Market by Country, 2018 - 2021, USD Thousands
- TABLE 22 LAMEA Gastrointestinal Diseases Market by Country, 2022 - 2028, USD Thousands
- TABLE 23 LAMEA Cancer Market by Country, 2018 - 2021, USD Thousands
- TABLE 24 LAMEA Cancer Market by Country, 2022 - 2028, USD Thousands
- TABLE 25 LAMEA Others Market by Country, 2018 - 2021, USD Thousands
- TABLE 26 LAMEA Others Market by Country, 2022 - 2028, USD Thousands
- TABLE 27 LAMEA Human Microbiome Market by Technology, 2018 - 2021, USD Thousands
- TABLE 28 LAMEA Human Microbiome Market by Technology, 2022 - 2028, USD Thousands
- TABLE 29 LAMEA Genomics Market by Country, 2018 - 2021, USD Thousands
- TABLE 30 LAMEA Genomics Market by Country, 2022 - 2028, USD Thousands
- TABLE 31 LAMEA Proteomics Market by Country, 2018 - 2021, USD Thousands
- TABLE 32 LAMEA Proteomics Market by Country, 2022 - 2028, USD Thousands
- TABLE 33 LAMEA Metabolomics Market by Country, 2018 - 2021, USD Thousands
- TABLE 34 LAMEA Metabolomics Market by Country, 2022 - 2028, USD Thousands
- TABLE 35 LAMEA Human Microbiome Market by Application, 2018 - 2021, USD Thousands
- TABLE 36 LAMEA Human Microbiome Market by Application, 2022 - 2028, USD Thousands
- TABLE 37 LAMEA Therapeutics Market by Country, 2018 - 2021, USD Thousands
- TABLE 38 LAMEA Therapeutics Market by Country, 2022 - 2028, USD Thousands
- TABLE 39 LAMEA Diagnostics Market by Country, 2018 - 2021, USD Thousands
- TABLE 40 LAMEA Diagnostics Market by Country, 2022 - 2028, USD Thousands
- TABLE 41 LAMEA Human Microbiome Market by Type, 2018 - 2021, USD Thousands
- TABLE 42 LAMEA Human Microbiome Market by Type, 2022 - 2028, USD Thousands
- TABLE 43 LAMEA Microbiome Consortia Transplantation (FMT) Market by Country, 2018 - 2021, USD Thousands
- TABLE 44 LAMEA Microbiome Consortia Transplantation (FMT) Market by Country, 2022 - 2028, USD Thousands
- TABLE 45 LAMEA Peptide Market by Country, 2018 - 2021, USD Thousands
- TABLE 46 LAMEA Peptide Market by Country, 2022 - 2028, USD Thousands
- TABLE 47 LAMEA Live Biotherapeutic Product Market by Country, 2018 - 2021, USD Thousands
- TABLE 48 LAMEA Live Biotherapeutic Product Market by Country, 2022 - 2028, USD Thousands
- TABLE 49 LAMEA Others Market by Country, 2018 - 2021, USD Thousands
- TABLE 50 LAMEA Others Market by Country, 2022 - 2028, USD Thousands
- TABLE 51 LAMEA Human Microbiome Market by Country, 2018 - 2021, USD Thousands
- TABLE 52 LAMEA Human Microbiome Market by Country, 2022 - 2028, USD Thousands
- TABLE 53 Brazil Human Microbiome Market, 2018 - 2021, USD Thousands
- TABLE 54 Brazil Human Microbiome Market, 2022 - 2028, USD Thousands
- TABLE 55 Brazil Human Microbiome Market by Product, 2018 - 2021, USD Thousands
- TABLE 56 Brazil Human Microbiome Market by Product, 2022 - 2028, USD Thousands
- TABLE 57 Brazil Human Microbiome Market by Disease Type, 2018 - 2021, USD Thousands
- TABLE 58 Brazil Human Microbiome Market by Disease Type, 2022 - 2028, USD Thousands
- TABLE 59 Brazil Human Microbiome Market by Technology, 2018 - 2021, USD Thousands
- TABLE 60 Brazil Human Microbiome Market by Technology, 2022 - 2028, USD Thousands
- TABLE 61 Brazil Human Microbiome Market by Application, 2018 - 2021, USD Thousands
- TABLE 62 Brazil Human Microbiome Market by Application, 2022 - 2028, USD Thousands
- TABLE 63 Brazil Human Microbiome Market by Type, 2018 - 2021, USD Thousands
- TABLE 64 Brazil Human Microbiome Market by Type, 2022 - 2028, USD Thousands
- TABLE 65 Argentina Human Microbiome Market, 2018 - 2021, USD Thousands
- TABLE 66 Argentina Human Microbiome Market, 2022 - 2028, USD Thousands
- TABLE 67 Argentina Human Microbiome Market by Product, 2018 - 2021, USD Thousands
- TABLE 68 Argentina Human Microbiome Market by Product, 2022 - 2028, USD Thousands
- TABLE 69 Argentina Human Microbiome Market by Disease Type, 2018 - 2021, USD Thousands
- TABLE 70 Argentina Human Microbiome Market by Disease Type, 2022 - 2028, USD Thousands
- TABLE 71 Argentina Human Microbiome Market by Technology, 2018 - 2021, USD Thousands
- TABLE 72 Argentina Human Microbiome Market by Technology, 2022 - 2028, USD Thousands
- TABLE 73 Argentina Human Microbiome Market by Application, 2018 - 2021, USD Thousands
- TABLE 74 Argentina Human Microbiome Market by Application, 2022 - 2028, USD Thousands
- TABLE 75 Argentina Human Microbiome Market by Type, 2018 - 2021, USD Thousands
- TABLE 76 Argentina Human Microbiome Market by Type, 2022 - 2028, USD Thousands
- TABLE 77 UAE Human Microbiome Market, 2018 - 2021, USD Thousands
- TABLE 78 UAE Human Microbiome Market, 2022 - 2028, USD Thousands
- TABLE 79 UAE Human Microbiome Market by Product, 2018 - 2021, USD Thousands
- TABLE 80 UAE Human Microbiome Market by Product, 2022 - 2028, USD Thousands
- TABLE 81 UAE Human Microbiome Market by Disease Type, 2018 - 2021, USD Thousands
- TABLE 82 UAE Human Microbiome Market by Disease Type, 2022 - 2028, USD Thousands
- TABLE 83 UAE Human Microbiome Market by Technology, 2018 - 2021, USD Thousands
- TABLE 84 UAE Human Microbiome Market by Technology, 2022 - 2028, USD Thousands
- TABLE 85 UAE Human Microbiome Market by Application, 2018 - 2021, USD Thousands
- TABLE 86 UAE Human Microbiome Market by Application, 2022 - 2028, USD Thousands
- TABLE 87 UAE Human Microbiome Market by Type, 2018 - 2021, USD Thousands
- TABLE 88 UAE Human Microbiome Market by Type, 2022 - 2028, USD Thousands
- TABLE 89 Saudi Arabia Human Microbiome Market, 2018 - 2021, USD Thousands
- TABLE 90 Saudi Arabia Human Microbiome Market, 2022 - 2028, USD Thousands
- TABLE 91 Saudi Arabia Human Microbiome Market by Product, 2018 - 2021, USD Thousands
- TABLE 92 Saudi Arabia Human Microbiome Market by Product, 2022 - 2028, USD Thousands
- TABLE 93 Saudi Arabia Human Microbiome Market by Disease Type, 2018 - 2021, USD Thousands
- TABLE 94 Saudi Arabia Human Microbiome Market by Disease Type, 2022 - 2028, USD Thousands
- TABLE 95 Saudi Arabia Human Microbiome Market by Technology, 2018 - 2021, USD Thousands
- TABLE 96 Saudi Arabia Human Microbiome Market by Technology, 2022 - 2028, USD Thousands
- TABLE 97 Saudi Arabia Human Microbiome Market by Application, 2018 - 2021, USD Thousands
- TABLE 98 Saudi Arabia Human Microbiome Market by Application, 2022 - 2028, USD Thousands
- TABLE 99 Saudi Arabia Human Microbiome Market by Type, 2018 - 2021, USD Thousands
- TABLE 100 Saudi Arabia Human Microbiome Market by Type, 2022 - 2028, USD Thousands
- TABLE 101 South Africa Human Microbiome Market, 2018 - 2021, USD Thousands
- TABLE 102 South Africa Human Microbiome Market, 2022 - 2028, USD Thousands
- TABLE 103 South Africa Human Microbiome Market by Product, 2018 - 2021, USD Thousands
- TABLE 104 South Africa Human Microbiome Market by Product, 2022 - 2028, USD Thousands
- TABLE 105 South Africa Human Microbiome Market by Disease Type, 2018 - 2021, USD Thousands
- TABLE 106 South Africa Human Microbiome Market by Disease Type, 2022 - 2028, USD Thousands
- TABLE 107 South Africa Human Microbiome Market by Technology, 2018 - 2021, USD Thousands
- TABLE 108 South Africa Human Microbiome Market by Technology, 2022 - 2028, USD Thousands
- TABLE 109 South Africa Human Microbiome Market by Application, 2018 - 2021, USD Thousands
- TABLE 110 South Africa Human Microbiome Market by Application, 2022 - 2028, USD Thousands
- TABLE 111 South Africa Human Microbiome Market by Type, 2018 - 2021, USD Thousands
- TABLE 112 South Africa Human Microbiome Market by Type, 2022 - 2028, USD Thousands
- TABLE 113 Nigeria Human Microbiome Market, 2018 - 2021, USD Thousands
- TABLE 114 Nigeria Human Microbiome Market, 2022 - 2028, USD Thousands
- TABLE 115 Nigeria Human Microbiome Market by Product, 2018 - 2021, USD Thousands
- TABLE 116 Nigeria Human Microbiome Market by Product, 2022 - 2028, USD Thousands
- TABLE 117 Nigeria Human Microbiome Market by Disease Type, 2018 - 2021, USD Thousands
- TABLE 118 Nigeria Human Microbiome Market by Disease Type, 2022 - 2028, USD Thousands
- TABLE 119 Nigeria Human Microbiome Market by Technology, 2018 - 2021, USD Thousands
- TABLE 120 Nigeria Human Microbiome Market by Technology, 2022 - 2028, USD Thousands
- TABLE 121 Nigeria Human Microbiome Market by Application, 2018 - 2021, USD Thousands
- TABLE 122 Nigeria Human Microbiome Market by Application, 2022 - 2028, USD Thousands
- TABLE 123 Nigeria Human Microbiome Market by Type, 2018 - 2021, USD Thousands
- TABLE 124 Nigeria Human Microbiome Market by Type, 2022 - 2028, USD Thousands
- TABLE 125 Rest of LAMEA Human Microbiome Market, 2018 - 2021, USD Thousands
- TABLE 126 Rest of LAMEA Human Microbiome Market, 2022 - 2028, USD Thousands
- TABLE 127 Rest of LAMEA Human Microbiome Market by Product, 2018 - 2021, USD Thousands
- TABLE 128 Rest of LAMEA Human Microbiome Market by Product, 2022 - 2028, USD Thousands
- TABLE 129 Rest of LAMEA Human Microbiome Market by Disease Type, 2018 - 2021, USD Thousands
- TABLE 130 Rest of LAMEA Human Microbiome Market by Disease Type, 2022 - 2028, USD Thousands
- TABLE 131 Rest of LAMEA Human Microbiome Market by Technology, 2018 - 2021, USD Thousands
- TABLE 132 Rest of LAMEA Human Microbiome Market by Technology, 2022 - 2028, USD Thousands
- TABLE 133 Rest of LAMEA Human Microbiome Market by Application, 2018 - 2021, USD Thousands
- TABLE 134 Rest of LAMEA Human Microbiome Market by Application, 2022 - 2028, USD Thousands
- TABLE 135 Rest of LAMEA Human Microbiome Market by Type, 2018 - 2021, USD Thousands
- TABLE 136 Rest of LAMEA Human Microbiome Market by Type, 2022 - 2028, USD Thousands
- TABLE 137 key information - Ferring Holdings SA
- TABLE 138 Key information - Enterome
- TABLE 139 KEY INFORMATION - Seres Therapeutics, Inc.
- TABLE 140 Key Information - 4D pharma plc
- TABLE 141 key Information - OptiBiotix Health Plc
- TABLE 142 Key Information - Synlogic, Inc.
- TABLE 143 Key Information - Second Genome, Inc.
- TABLE 144 Key Information - Vedanta Biosciences, Inc.
- TABLE 145 key information - Finch Therapeutics Group, Inc.
